Loading clinical trials...
Loading clinical trials...
COPD is characterized by exagerated decline FEV1 related to obstructive non reversible airflow. This could be the consequence of structural changes and inflammatory pattern of the bronchial wall. Lesions could lead to normal but also abnormal remodeling specially in COPD including a decrease in Club cells number and function.There is no treatment actually available targeted to a normal repair of the epithelium. The objective of this work is to identify potential targets for reprograming bronchial epithelial cells I order to achieve a good repair.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Pneumology Department
Montpellier, France
Start Date
October 17, 2014
Primary Completion Date
April 17, 2018
Completion Date
April 17, 2018
Last Updated
September 24, 2019
30
ACTUAL participants
In vitro experiments on bronchial epithelial cells
OTHER
Lead Sponsor
University Hospital, Montpellier
NCT07477600
NCT07462221
NCT07351929
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions